Keyphrases
Cardiovascular Outcomes
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Cardiovascular Risk
16%
Inflammation
16%
Diabetes
16%
Kidney
16%
Clinical Data
16%
Patients with Diabetes
16%
Cardioprotection
16%
Cardiac Outcomes
16%
Sodium-hydrogen Exchanger
16%
Myocardial Energy Metabolism
16%
Pleotropic Effects
16%
National Cohort Study
16%
Progression to Diabetes
16%
EMPA-REG
16%
Medicine and Dentistry
Cardiovascular System
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Diabetes
33%
Atherosclerosis
16%
Energy Transfer
16%
Cohort Analysis
16%
Patient with Diabetes
16%
Sodium Proton Exchange Protein
16%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2 Inhibitor
100%
Atherosclerosis
16%
Inflammation
16%
Cohort Study
16%
Sodium Proton Exchange Protein
16%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
16%